Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole α(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH)

Journal of Medicinal Chemistry

Volumn 43, Issue 8, 2000, Pages 1586-1603

  Meyer, Michael D ^a   Altenbach, Robert J ^a   Basha, Fatima Z ^a   Carroll, William A ^a   Condon, Stephen ^a   Elmore, Steven W ^a   Kerwin Jr , James F ^a   Sippy, Kevin B ^a   Tietje, Karin ^a   Wendt, Michael D ^a   Hancock, Arthur A ^a   Brune, Michael E ^a   Buckner, Steven A ^a   Drizin, Irene ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (6 METHOXY 2,3,3A,4,5,9B HEXAHYDRO[1H] BENZ[E]ISOINDOL 2 YL)ETHYL] 8 CHLORO PYRAZINOL[2'3':4,5]THIENOL[3,2 DEXTRO]PYRIMIDINE 2,4(1H,3H) DIONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; IN VITRO STUDY; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PROSTATE HYPERTROPHY; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CELL LINE; DOGS; HETEROCYCLIC COMPOUNDS, 3-RING; INDOLES; MALE; PRESSURE; PROSTATIC HYPERPLASIA; RADIOLIGAND ASSAY; RATS; RATS, INBRED SHR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; URETHRA;

EID: 0034692176     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990567u     Document Type: Article

References (43)

1. Shapiro, E.; Lepor, H. Pathophysiology of Clinical Benign Prostatic Hyperplasia. Urol. Clin. N. Am. 1995, 22, 285-290. Lee, C.; Kozlowski, J. M.; Grayhack, J. T. Etiology of Benign Prostatic Hyperplasia. Urol. Clin. N. Am. 1995, 22, 237-46.
2. Shapiro, E.; Lepor, H. Pathophysiology of Clinical Benign Prostatic Hyperplasia. Urol. Clin. N. Am. 1995, 22, 285-290. Lee, C.; Kozlowski, J. M.; Grayhack, J. T. Etiology of Benign Prostatic Hyperplasia. Urol. Clin. N. Am. 1995, 22, 237-46.
3. Caine, M.; Pfau, A.; Perlberg, S. The Use of Alpha Adrenergic Blockers in Benign Prostatic Obstruction. Br. J. Urol. 1976, 48, 255-63.
4. 1-Adrenoceptor Selectivity? Br. J. Urol. 1995, 76, Suppl. 1, 47-55.
5. 1-Adrenoceptor Selectivity? Br. J. Urol. 1995, 76, Suppl. 1, 47-55.
6. 1-Adrenoceptor Selectivity? Br. J. Urol. 1995, 76, Suppl. 1, 47-55.
7. Lepor, H.; Henry, D.; Laddu, A. R. The Efficacy and Safety of Terazosin in the Treatment of BPH. Prostate 1991, 18, 345-355.
8. Holme, J. B.; Christensen, M. M.; Rasmussen, P. C.; Jacobsen, F.; Nielsen, J.; Norgaard, J. P.; Olesen, S.; Noer, L.; Wolf, H.; Husted, S. E. 29-Week Doxazosin Treatment in Patients with Symptomatic Benign Prostatic Hyperplasia. Scand. J. Urol. 1994, 28, 77-82.
9. 1-Blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy. J. Urol. 1990, 154, 908-912.
10. Jardin, A.; Bensadoun, H.; Delauche-Cavallier, M. C.; Stalla-Bourdillon, A.; Attali, P. Long-term Treatment of Benign Prostatic Hyperplasia with Alfuzosin: a 24-30 month Survey. Br. J. Urol. 1984, 74, 579-584.
11. 1-Adrenoceptors: Consensus Update. Pharmacol. Rev. 1995, 47, 267-70.
12. 1-Adrenoceptors: Consensus Update. Pharmacol. Rev. 1995, 47, 267-70.
13. 1-Adrenoceptor Subtype mRNAs in Human Prostate: Comparison of Benign Hypertrophied Tissue and Non-Hypertrophied Tissue. Br. J. Pharmacol. 1996, 119, 797-803. Price, D. T.; Scwhinn, D. A.; Lomasney, J. W.; Allen, L. F.; Caron, M. G.; Lefkowitz, R. J. Identification, Quantitation, and Localization of mRNA for three Distinct Alphal-Adrenergic Subtypes in Human Prostate. J. Urol. 1993, 150, 546-51.
14. 1-Adrenoceptor Subtype mRNAs in Human Prostate: Comparison of Benign Hypertrophied Tissue and Non-Hypertrophied Tissue. Br. J. Pharmacol. 1996, 119, 797-803. Price, D. T.; Scwhinn, D. A.; Lomasney, J. W.; Allen, L. F.; Caron, M. G.; Lefkowitz, R. J. Identification, Quantitation, and Localization of mRNA for three Distinct Alphal-Adrenergic Subtypes in Human Prostate. J. Urol. 1993, 150, 546-51.
15. 1c Subtype. Mol. Pharmacol. 1994, 45, 703-08.
16. 1c Subtype. Mol. Pharmacol. 1994, 45, 703-08.
17. 1-Antagonist Selective for Lower Urinary Tract: In Vivo Studies. Neuourol. Urodyn. 1994, 13, 471-472.
18. 1-Antagonist Selective for Lower Urinary Tract: In Vivo Studies. Neuourol. Urodyn. 1994, 13, 471-472.
19. 1-Antagonist Selective for Lower Urinary Tract: In Vivo Studies. Neuourol. Urodyn. 1994, 13, 471-472.
20. 1b-Adrenergic Receptor. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 11589-11594.
21. 1-Adrenoceptor Subtypes in Human Bladder Detrusor. J. Urol. 1998, 159, 329.
22. Broten, T.; Scott, A.; Siegl, P. K. S.; Forray, C.; Lagu, B.; Nagarathnam, W. C.; Marzabadi, W. M.; Murali Dhar, T. G.; Gluckowski, C. Alpha-1 Adrenoceptor Blockade Inhibits Detrusor Instability in Rats With Bladder Outlet Obstruction. FASEB J. Abst. 1998, 12, A445.
23. A-Receptors. Eur. J. Med. Chem. 1993, 28, 499-504.
24. 2-Antagonistic Activities. J. Med. Chem. 1997, 40, 1049.
25. DeBernardis, J. F.; Meyer, D.M.; Sippy, K. B. Preparation of Alkoxyhexahydrobenzindoles, -Indenopyrroles and -Indenopyridines as Selective 5-HT Receptor Agents. U.S. Patent No. 5,049,564, 1991.
26. DeBernardis, J. F.; Meyer, D. M.; Sippy, K. B. 5-HT Selective Agents. U.S. Patent 5,244,888, 1993.
27. Winstein, S.; Heck, R. F. Aryl Participation in the Solvolysis of some gem-Dimethyl-Substituted 4-Aryl-alkyl p-Bromobenzene-sulfonates. J. Org. Chem. 1972, 37, 825-836.
28. Beck, J. R. A Direct Synthesis of Benzo[bt]thiophene-2-carboxylate Esters Involving Nitro Displacement J. Org. Chem. 1972, 37, 3224.
29. Dunn, A. D.; Norrie, R. Nucleophilic Displacements in Pyridine Rings. J. Heterocycl. Chem. 1987, 24, 85.
30. Hieble, J. P.; Boyce, A. J.; Caine, M. Comparison of the al-Adrenoceptor Characteristics in Human and Canine Prostate. Fed. Proc. 1986, 45 (11), 2609-2614.
31. 1b-Adrenoceptor Mediating Contraction of the Rat Spleen. Br. J. Pharmacol. 1993, 115, 467-475.
32. 1A Receptor Subtype. J. Pharmacol. Exp. Ther. 1995, 274, 97-103.
33. Brune, M. E.; Buckner, S. A.; Polakowski, J.; Kerwin, J. F.; Hancock, A. A. Pharmacological Antagonism of Alpha-Adrenergic Agonist Induced Increases in Canine Intraurethral Pressure In Vivo. Drug Dev. Res. 1995, 34, 267-275.
34. Gorvin, J. H. Pharmaceutical Composition Containing Acridone and Xanthone Compounds. U.S. Patent No. 4,250,182, 1981.
35. Markley L. D.; Tong, J. C.; Dulworth, J. K.; Steward, D. L.; Goralski, C. T.; Johnston, H.; Wood, S. G.; Vinogradoff, A. P.; Bargar, T. M. Antipicornavirus Activity of Substituted Phenoxybenzenes and Phenoxypyridines. J. Med. Chem. 1986, 29, 427.
36. De Angelis, G. G.; Hess, H. J. E. Benzothieno- and Benzofuro-[3,2-d]pyrimidine Inhibitors of Platelet Aggregation. U.S. Patent 3,706,747, 1972.
37. Schneller, S. W.; Clough, F. W.; Hardee, L. E. A Simple Synthesis of Thieno[2,3-b]pyrazine and Thieno[2,3-b]pyridine. J. Heterocycl. Chem. 1975, 12, 513.
38. Brederick, H.; Simchen, G.; Traut, H. Zur Pyrimidin-Synthese aus Tris-formamino-methan and CH-aciden Verbindungen. Chem. Ber. 1965, 98, 3883.
39. Yamanaka, H.; Sakamoto, T.; Nishimura, S.; Sagi, M. Studies on Pyrimidine Derivatives. XXXIX. Site-Selectivity in the Reaction of 5-Substituted and 4,5-Disubstituted Pyrimidine N-Oxides with Trimethylsilyl Cyanide. Chem. Pharm. Bull. 1987, 35, 3119.
40. Dick, G. P. G.; Wood, H. C. S. Pteridine Derivatives. Part I. A New Synthesis of 2-Amino-4-Hydroxypteridines. J. Chem. Soc. 1955, 1379.
41. Jones, R. G. Pyrazines and Related Compounds I. A New Synthesis of Hydroxypyrazines. J. Am. Chem. Soc. 1949, 71, 78.
42. Beck, J. R.; Yahner, J. A. Synthesis of [1]Benzothieno[3,2-d]-pyrimidine Derivatives. J. Org. Chem. 1973, 38, 2450.
43. Dinitriles epimerize under the reaction conditions. It seems likely that the trans dinitrile is converted to trans benzoisoindole at a greater rate than the cis dinitrile, leading to predominant formation of trans benzoisoindole in accordance with Curtin-Hammett principle.